{"schema_version":"secwatch.filing_event.v1","accession":"0000875320-24-000231","form_type":"8-K","ticker":"VRTX","cik":"0000875320","company_name":"VERTEX PHARMACEUTICALS INC / MA","filed_at":"2024-12-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:11.196166+00:00","generated_at":"2026-05-29T00:44:17.955605+00:00","sec_items":["7.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Vertex receives FDA approval for new CF drug ALYFTREK; wholesale cost $370K/year","bullets":["FDA approved ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor) for CF in patients 6+ years with at least one F508del mutation.","Annual wholesale acquisition cost in the U.S. is $370,269 ($28,404 per 28-day pack).","Approval expands Vertex's cystic fibrosis treatment portfolio."],"urls":{"canonical":"https://secwatch.observer/filing/0000875320-24-000231","json":"https://secwatch.observer/filing/0000875320-24-000231.json","markdown":"https://secwatch.observer/filing/0000875320-24-000231.md","text":"https://secwatch.observer/filing/0000875320-24-000231.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/875320/000087532024000231/0000875320-24-000231-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/875320/000087532024000231/vrtx-20241220.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T00:44:17.955605+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}